Literature DB >> 24857272

The effectiveness of 4.5F ultrathin semirigid ureteroscope in the management of ureteral stones in prepubertal children: is there a need for any ureteral dilatation?

Canan Kocaoglu1, Keramettin Ugur Ozkan2.   

Abstract

OBJECTIVE: To evaluate the effectiveness of 4.5F ultrathin semirigid ureteroscope (ultrathin-URS) in the management of ureteral stones in prepubertal children without active or passive ureteral dilatation.
MATERIALS AND METHODS: Records of 36 children undergoing ureteroscopy with ultrathin-URS were retrospectively reviewed in 2 different centers for ureteral calculi between November 2011 and December 2013. Stones were fragmented with holmium:yttrium-aluminum-garnet laser and pneumatic lithotripter. Patients' demographics, stone location and size, active dilatation, passive dilatation, postoperative stenting, stone-free rates, and complications were noted.
RESULTS: Patients consisted of 21 girls and 15 boys with a mean age of 5.33±3 years. Stones were located in the distal, mid, and proximal ureter in 26, 5, and 5 patients, respectively. All ureteroscopies were performed with no active or passive dilatation. Ultrathin-URS was able to provide a stone-free status in the first procedure except 1 patient whose stone was too proximal. Postoperative ureteral stents (post-stenting) had initially been placed in 16 procedures at the end of the procedure to maintain the ureteral passage. However, after increasing occupational experience and learning that ureteral traumas were minimal with ultrathin-URS, no postoperative stent was used in the following procedures. As to complications, only 3 patients had mild hematuria, and 1 patient had febrile urinary tract infection, and 1 stone migration. No ureteral perforation, obstruction and avulsion were encountered.
CONCLUSION: In ureteral stone management, ultrathin-URS along with either holmium:yttrium-aluminum-garnet laser or pneumatic lithotripter can be safely and effectively used with a minimal morbidity as a first-line treatment in prepubertal children without active or passive ureteral dilatation and postoperative stenting.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24857272     DOI: 10.1016/j.urology.2014.03.027

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  The effect of ureteroscope size in the treatment of ureteral stone: 15-year experience of an endoscopist.

Authors:  Muhammet Fatih Kılınç; Ömer Gökhan Doluoğlu; Tolga Karakan; Ayhan Dalkılıç; Nurettin Cem Sönmez; Cem Nedim Yücetürk; Berkan Reşorlu
Journal:  Turk J Urol       Date:  2016-06

2.  Experience of retaining encrusted ureteral stents: URL by 4.5/6.5F ureteroscope can reduce the possibility of PCNL.

Authors:  Zhaohui He; Hanqi Lei; Caixia Zhang; Hangtao Wang; Fucai Tang; Guohua Zeng
Journal:  Urolithiasis       Date:  2017-06-12       Impact factor: 3.436

3.  Extending indications of micropercutaneous nephrolithotomy: It is not just about cracking stones.

Authors:  Arvind P Ganpule; Jaspreet Singh Chhabra; S B Sudharsan; Ankush Jairath; Mohankumar Vijaykumar; Ravindra Sabnis; Mahesh R Desai
Journal:  Arab J Urol       Date:  2017-01-07

4.  Successful Ultra-Minimally Invasive Endoscopic Intrarenal Surgery for 2-Year-Old Boy with Bilateral Cystine Kidney Stones Over 2 cm.

Authors:  Takaaki Inoue; Masato Watanabe; Seiji Shimada; Hidefumi Kinoshita; Tadashi Matsuda
Journal:  J Endourol Case Rep       Date:  2018-07-01

5.  Is the 4.5-F ureteroscope (Ultra-Thin) an alternative in the management of ureteric and renal pelvic stones?

Authors:  Hakkı Uzun; Nezih Akça
Journal:  Arab J Urol       Date:  2018-06-21

6.  Microureteroscopy in Children: Two First Cases.

Authors:  Juan-Pablo Caballero-Romeu; Alberto Budia-Alba; Juan-Antonio Galan-Llopis; Maria-Dolores Montoya-Lirola; Pedro-José García-Tabar; Juan-Francisco Galiano-Baena; Nuria Albertos-Mira-Marcelí; Jeronimo Gonzalvez-Piñera
Journal:  J Endourol Case Rep       Date:  2016-03-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.